AbbVie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO®
Key takeaways
- (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO® Noor Ul Ain Rehman Tue, June 2, 2026 at 9:42 PM GMT+7 2 min read ABBV Abb Vie Inc.
- (NYSE:ABBV) further clarified that the European Commission authorization extends to all European Union Member States, and includes Iceland, Norway, and Liechtenstein.
- While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.
Abb Vie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO® Noor Ul Ain Rehman Tue, June 2, 2026 at 9:42 PM GMT+7 2 min read ABBV Abb Vie Inc. (NYSE:ABBV) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. Abb Vie Inc. (NYSE:ABBV) announced on May 29 authorization by the European Commission (EC) for an expanded label for VENCLYXTO® to include use in combination with acalabrutinib (with or without obinutuzumab), along with use in combination with ibrutinib to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL). Management stated that the expanded label follows the EC’s inclusion of these combinations in the acalabrutinib and ibrutinib labels, with all-oral, fixed-duration combination regimens supporting the current standards of care. It added that they can also offer providers and patients additional targeted oral medications for CLL in the first-line setting that include the potential for time off treatment.
AbbVie Inc. (NYSE:ABBV) further clarified that the European Commission authorization extends to all European Union Member States, and includes Iceland, Norway, and Liechtenstein. Svetlana Kobina, MD, PhD, vice president, global medical affairs, oncology, AbbVie, stated that the VENCLYXTO-based combination regimens exhibited “a favorable efficacy and safety profile in the first-line setting for chronic lymphocytic leukemia”.
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.